Read more

December 13, 2021
6 min watch
Save

VIDEO: Real-world data highlights urgent need for effective therapies for HRS-AKI

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this Healio Gastroenterology video exclusive, Arun J. Sanyal, MD, professor of medicine at Virginia Commonwealth University, discussed real-world data on patient characteristics, treatment and clinical response in hepatorenal syndrome.

Sanyal and colleagues retrospectively assessed medical charts from 132 patients across 11 hospitals in the United States with hepatorenal syndrome-acute kidney injury (HRS-AKI).

He noted HRS-AKI is a very severe disease and the median mortality rate was 0.6 months.

“The results of this study did not support a link between disease severity at presentation and response to treatment,” Sanyal said.

He said the study highlights the urgent need to develop effective therapies for HRS-AKI.